Skip to content
Witfire Elite • Pharma intelligence
Submit intelligence

Witfire Elite Pharma News

Pharma business news, market intelligence, and CEO-level case studies

Signal Oral PCSK9 Inhibitor Approved: LIPFENDRA Price vs Repatha Jul 17, 2026

Witfire Desk

Latest Pharma Intelligence

New reports, regulatory signals, deal autopsies and market consequence analysis from the Witfire desk.

Witfire Desk

Regulatory Radar

FDA decisions, CRLs, advisory committee signals, CMC issues and launch-risk interpretation.

View all

Witfire Desk

Market Case Studies

Deal, launch, market-share and strategic consequence analysis.

View all

Witfire Desk

Capital & Stock Market

Pharma valuation, financing, licensing, stock-market exposure and policy-risk movement.

View all

Witfire Desk

Asia & Emerging Market Watch

India, Philippines, Asia and emerging healthcare market developments.

View all

Decision Table

Decision Radar

A fast index of recent pharma events, categories and business consequences.

Date Signal Category Read
Moderna Flu Vaccine Reversal: FDA Refused to Review It—Then Advisers Voted 9-0 Twice FDA & Regulatory Intelligence, Pharma News Open
FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma FDA & Regulatory Intelligence Open
India’s Generic Ozempic Boom Is a Margin Trap—and the Price Collapse It Started Has Now Reached the US Pharma Market Case Studies, Pharma News Open
FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug FDA & Regulatory Intelligence, FDA & Regulatory Intelligence, Pharma Market Case Studies, Pharma News Open
IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion Pharma Market Case Studies, Pharma News Open
Fulcrum’s Pociredir Collapse: How FDA’s PRC2 Risk View Crushed a Data-Rich Sickle Cell Drug Pharma Market Case Studies, Pharma News Open
IQVIA Signal: Wegovy Pill May Expand the GLP-1 Market, Not Just Replace Injections FDA & Regulatory Intelligence, Pharma Market Case Studies, Pharma News Open
FDA’s Digital Liver Break: How AI Toxicology Could Change Drug Development Before Phase I FDA & Regulatory Intelligence, Pharma Market Case Studies, Pharma News Open

Keep reading the desk

Every Witfire report is source-backed and written for the business consequence, not the headline.

Browse all pharma intelligence
Witfire monthly intelligence issue cover
Monthly Intelligence Issue
Magazine asset / PDF / special report

Flagship Product

Chokepoints & Catalysts — Vol. I, No. 1

Five intelligence-led analyses on how FDA decisions, geopolitical chokepoints, and policy shifts are repricing global pharma.

Read Witfire magazine

Trust Layer

Source Ledger

A visible trust system for pharma readers, investors, founders, researchers and media platforms.

Regulators FDA, EMA, MHRA, CDSCO, WHO and official decision documents.
Companies Press releases, SEC filings, investor decks and exchange disclosures.
Clinical Evidence Trial registries, abstracts, publications, endpoints and safety signals.
Market Context Capital movement, policy shifts, CDMO risk, pricing pressure and launch execution.

Submit company news

For regulatory milestones, funding, CEO features, product launches and scientific announcements.

Open contact page

Advertising policy

Sponsored content, media partnerships and native advertising need clear labeling and claim support.

Read policy

Corrections

A clear correction route strengthens publisher trust with readers and platforms.

Request correction